Kymera Therapeutics (KYMR) financial statements
Kymera Therapeutics reported revenue of $39M in fiscal 2025, up 54.0% a year over 6 years.
Net income was -$311M and the operating margin -891.1%, against -1438.5% in 2019.
Free cash flow was -$234M.
The diluted share count rose 4874% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Kymera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $3M | $34M | $73M | $47M | $79M | $47M | $39M |
| Cost of revenue | — | — | — | $47M | $79M | $47M | $39M |
| Research and development | $37M | $62M | $137M | $164M | $189M | $240M | $317M |
| Selling, general and admin | $8M | $18M | $36M | $44M | $55M | $64M | $68M |
| Operating income | -$42M | -$46M | -$101M | -$161M | -$166M | -$262M | -$349M |
| Pre-tax income | — | — | — | — | — | — | -$311M |
| Income tax | $0 | $0 | $0 | $0 | — | — | $0 |
| Net income | -$41M | -$46M | -$100M | -$155M | -$147M | -$224M | -$311M |
| EPS (diluted) | -$24.28 | -$3.15 | -$2.09 | -$2.87 | -$2.52 | -$2.98 | -$3.69 |
| Diluted shares | 2M | 17M | 48M | 54M | 58M | 75M | 84M |
| Operating margin | -1438.5% | -136.1% | -138.0% | -344.4% | -210.6% | -555.8% | -891.1% |
| Net margin | -1405.8% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.0% |
Balance sheet
Fiscal years, from Kymera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $92M | $296M | $442M | $407M | $375M | $489M | $848M |
| Receivables | — | — | — | $0 | $15M | $0 | $0 |
| Total current assets | $93M | $302M | $451M | $419M | $405M | $510M | $871M |
| Property, plant and equipment | $4M | $11M | $12M | $13M | $48M | $50M | $43M |
| Total assets | $117M | $487M | $606M | $603M | $576M | $978M | $1.7B |
| Total current liabilities | $35M | $111M | $93M | $71M | $86M | $68M | $83M |
| Total liabilities | $82M | $203M | $146M | $113M | $181M | $142M | $163M |
| Shareholders' equity | -$74M | $284M | $460M | $490M | $395M | $836M | $1.6B |
| Net debt | -$76M | -$31M | -$48M | -$68M | -$110M | -$120M | -$357M |
Cash flow
Fiscal years, from Kymera Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $18M | $88M | -$129M | -$153M | -$103M | -$195M | -$233M |
| Capital spending | $532,000 | $9M | $2M | $3M | $34M | $13M | $1M |
| Free cash flow | $17M | $79M | -$131M | -$156M | -$137M | -$207M | -$234M |
| Stock-based compensation | $1M | $5M | $25M | $35M | $43M | $55M | $60M |
| Free cash flow margin | 592.1% | 232.2% | -179.2% | -333.0% | -174.7% | -440.5% | -597.6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for KYMR.
Open KYMR in InvestinglyQuestions
What was Kymera Therapeutics's revenue in 2025?
$39M in fiscal 2025, from its 10-K filing.
How much free cash flow does Kymera Therapeutics generate?
-$234M in fiscal 2025 (operating cash flow minus capital spending).
From Kymera Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.